RESUMEN
The purpose of this study was to evaluate the influence of fibrin glue and aprotinin on the growth of adult human skin keratinocytes in defined serum-free conditions. The keratinocytes were cultured on cell culture plastics and on a fibrin matrix prepared from fibrin glue. The cell growth was measured by MTT assay, while the growth of clonogenic keratinocytes was evaluated by colony assay and expressed as colony-forming efficiency (CFE). The clonogenic potential of keratinocytes released from subconfluent and confluent cultures grown on fibrin glue was also studied by the colony assay. In comparison to a plastic culture surface the fibrin glue had significantly (P<0.05) increased the clonogenic potential of keratinocytes, as well as enhanced their growth. Keratinocytes released from subconfluent cultures grown on fibrin glue attained a significantly (P<0.05) higher percentage of clonogenic cells than their confluent parallels. At 75, 150, 300 and 450 KIU/ml aprotinin did not influence the growth of keratinocytes (P>0.2). A fibrin-based skin substitute produced in the defined keratinocyte medium could be safely used to treat a number of skin defects.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Adhesivo de Tejido de Fibrina/síntesis química , Queratinocitos/química , Piel Artificial , Aprotinina/farmacología , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Adhesivo de Tejido de Fibrina/metabolismo , Humanos , Queratinocitos/citología , Queratinocitos/efectos de los fármacos , Sales de TetrazolioRESUMEN
Platelets, which contain many growth factors such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta), are being used in clinical applications as platelet-rich plasma (PRP). Only a few studies, however, have been conducted on the growth factors present in PRP and on the clinical applications using the drug delivery system (DDS). For the purpose of clinical application, we first modified the PRP preparation method and assessed the amounts of growth factors contained in the human platelet concentrates. Furthermore, we assessed fibrin glue as a DDS of platelet concentrates. Platelet precipitations were made by twice centrifuging human whole blood. The precipitated platelet was resuspended to yield the platelet concentrates. The growth factor concentrations were measured. Fibrin glue sheets containing this platelet concentrate were implanted in rabbit pinna and samples were obtained for immunostaining (anti-PDGF antibody) to assess the use of PRP over time using the fibrin glue as the DDS. The mean concentration of growth factors present in the platelet concentrates was three times or greater than that of conventional PRP. Furthermore, the results indicated that when the platelet concentrate was used with fibrin glue as a carrier, the contents were released over a period of about 1 week. This raises the possibility that this system may be useful in clinical applications.
Asunto(s)
Plaquetas/metabolismo , Plasma/citología , Transfusión de Plaquetas/métodos , Adulto , Animales , Transfusión de Sangre Autóloga , Centrifugación , Sistemas de Liberación de Medicamentos , Femenino , Adhesivo de Tejido de Fibrina/metabolismo , Sustancias de Crecimiento/metabolismo , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Factor de Crecimiento Derivado de Plaquetas/biosíntesis , Conejos , Factores de Tiempo , Factor de Crecimiento Transformador beta/sangreRESUMEN
BACKGROUND: Although fibrin sealant (Beriplast, Aventis Behring, Marburg, Germany) has been widely used as a supplementary measure for hemostasis during cardiac surgery in Europe and is becoming popular in the United States, the pharmocokinetics of fibrin sealant applied in pericardial space has not been elucidated. METHODS: A small incision was made on the epicardial surface of the left ventricle of a rat, and the incision was sutured. Total 0.2 ml of fibrin sealant containing iodine 125 (125I)-labeled fibrinogen, aprotinin, blood coagulation factor XIII and thrombin was applied to the area around the suture line. RESULTS: Distributions of 125I-labeled fibrinogen in the heart on postoperative days 1, 3, 7, and 14 were 48.2% +/- 1.8%, 20.7% +/- 2.2%, 0.15% +/- 0.02%, and 0.01% +/- 0.02%, respectively. The radioactivity was negligible in the blood, liver, spleen, and kidney except for the thyroid in which the radioactivity increased to 7.9% +/- 0.7% and 4.3% +/- 0.4%, respectively, on postoperative days 7 and 14. Iodine 125-labeled fibrinogen concentrations of the heart and other organs showed a similar change in the time course of distribution. Dense and thick fibrin network, observed on postoperative day 1, had dissipated and was thinner with collagen formation by postoperative day 7. CONCLUSIONS: Fibrin sealant applied to the pericardial cavity regresses rapidly and plays an important role in wound healing.
Asunto(s)
Adhesivo de Tejido de Fibrina/metabolismo , Pericardio/patología , Animales , Masculino , Microscopía Electrónica de Rastreo , Ratas , Ratas Sprague-Dawley , Distribución Tisular , Cicatrización de Heridas/fisiologíaRESUMEN
The use of implants to stabilize fractured diaphyseal bone, to handle difficult bone damage and to perform augmentation or replacement procedures in bone has become a common method in bone surgery. In most cases metal implants were used. Biodegradability of implant materials offers new perspectives. Restoration of the physiological status in the implant site becomes possible. Allergic reaction and second operations to remove the implants can be avoided and transitional aid in wound healing by the use of biomaterials can be achieved. An in-vitro system was established to investigate the interactions between osteoclasts and biomaterials, since it is the osteoclasts which are potentially able to resorb or degrade implants. The cell's resorption capabilities as well as its morphological behavior were documented. Two biodegradable and four nonbiodegradable materials were tested. The non-degradable materials provoked specific cell behaviour patterns but were not resorbed. Fibrin tissue adhesive sealant, however, displayed resorption lacunae mediated by osteoclasts, whereas polydioxanone (PDS) showed no resorption sites but normal cellular morphology when compared to the standard control (cells on hydrophilic coated teflon dishes). Both materials appeared to be well accepted by osteoclasts. This test system was established for the valuation of biodegradable implant materials and can be used to characterize new materials concerning their resorbability and biocompatibility without superposition by other cell systems.